Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Genitrix LLC
Profile last edited on: 12/19/14      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1998
First Award
1997
Latest Award
2006
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1 Emerson Place Unit 9h
Boston, MA 02114
   (617) 742-3954
   eyoung@genitrix.com
   N/A
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

Genitrix, a research-based, creativity-driven biotechnology company, is developing products that stimulate the immune system to fight chronic infections and other serious diseases. These products allow the immune system to recognize, remember, and respond to insidious disease-causing agents. Our technology elicits a robust cellular immune response that can eliminate unwanted "intruders".

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
1
Conversion Rate
16.67%
Phase I Dollars
$863,878
Phase II Dollars
$862,317
Total Awarded
$1,726,195

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2006 2 NIH $1,069,260
Project Title: HA Based Opsonokines:A Novel Approach to Tumor Vaccines
2003 1 NIH $148,163
Project Title: DNA Vaccines for Anthrax: Targeting Afferent Immunity
2000 1 NIH $204,019
Project Title: Engineered Opsonins for Whole Cell Tumor Vaccines
1999 1 NIH $105,190
Project Title: Whole Cell Tumor Vaccines Based On Gpi Linked Molecule
1999 1 NIH $100,681
Project Title: Development of Tumor Vaccines Using GPI-Linked Molecules

Key People / Management

  Andrew H Segal -- President

  Brian Lajoie

  Christopher Pugh

  Elihu Young

Company News

There are no news available.